Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Revenue of Atara Biotherapeutics, Inc. (ATRA)
Revenue in 2023 (TTM): $8.57 M
According to Atara Biotherapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $8.57 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Atara Biotherapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $8.57 M | $-313,000 | $-264,447,000 | $-276,111,000 | $-2,761,260,000 |
| 2022 | $63.57 M | $49.01 M | $-330,750,000 | $-228,290,000 | $-2,283,020,000 |
| 2021 | $20.34 M | $8.96 M | $-340,462,000 | $-340,095,000 | $-3,401,410,000 |
| 2020 | $ | $-9,867,000 | $-309,052,000 | $-306,605,000 | $-3,066,200,000 |
| 2019 | $ | $-8,105,000 | $-295,681,000 | $-290,964,000 | $-2,909,760,000 |
| 2018 | $ | $-3,781,000 | $-237,111,000 | $-230,743,000 | $-2,306,990,000 |
| 2017 | $ | $-956,000 | $-121,532,000 | $-119,505,000 | $-1,194,910,000 |
| 2016 | $ | $-383,000 | $-81,242,000 | $-79,039,000 | $-790,490,000 |
| 2015 | $ | $-48,000 | $-58,448,000 | $-57,230,000 | $-572,210,000 |
| 2014 | $ | $ | $-28,156,000 | $-28,031,000 | $-280,060,000 |
| 2013 | $ | $ | $-8,611,000 | $-8,603,000 | $-87,730,000 |
| 2012 | $ | $ | $-9,054,000 | $-12,279,000 | $-123,300,000 |